Market Cap 509.87M
Revenue (ttm) 311.71M
Net Income (ttm) 163.06M
EPS (ttm) N/A
PE Ratio 3.66
Forward PE 9.49
Profit Margin 52.31%
Debt to Equity Ratio 0.00
Volume 1,899,200
Avg Vol 2,768,654
Day's Range N/A - N/A
Shares Out 79.05M
Stochastic %K 30%
Beta 1.31
Analysts Strong Sell
Price Target $14.43

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was in...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 517 9500
Address:
389 Interpace Pkwy, Suite 450, Parsippany, United States
Brunoez
Brunoez Mar. 16 at 2:45 AM
$CRMD FWIW, I contacted my legislators in GA re: the Kidney Care Act. I received a reply from Raphael Warnock, and he indicated he will vote in favor.
0 · Reply
Noname2022
Noname2022 Mar. 16 at 12:17 AM
$CRMD Real world study, Rezzayo 91% effective (treatment) https://healix.net/wp-content/uploads/Hengel-et-al_IDWeek-2025_Rezafungin-Poster_09-24-2025.pdf
0 · Reply
Noname2022
Noname2022 Mar. 15 at 6:27 PM
$CRMD In HSCT prophylaxis studies, echinocandins show low Aspergillus breakthrough rates. In the randomized micafungin trial (van Burik 2004), 1 Aspergillus case occurred among 425 patients (~0.24%), vs 7 among 457 fluconazole patients (~1.5%). An MD Anderson caspofungin cohort (n=123) reported 3 Aspergillus infections (~2.4%). Micafungin and caspofungin are echinocandins, suggesting class activity. For comparison, posaconazole vs fluconazole showed 2.3% vs 7.0% aspergillosis (NEJM 2007). Rezafungin is also an echinocandin, with potential advantages including loading-dose exposure and higher tissue penetration.
0 · Reply
look_at_that_
look_at_that_ Mar. 15 at 4:34 PM
$CRMD Defencath will soon be the default lock solution for all eligible CVC patients at US Renal. I wonder if they are defining eligible as high risk FFS patients with a catheter or all FFS patients with a catheter across the board regardless of risk level. Either way it’s a positive.
0 · Reply
stevemail
stevemail Mar. 15 at 6:18 AM
$CRMD Joe needs to sell this for 1billion
0 · Reply
wolfofwestloop
wolfofwestloop Mar. 15 at 1:30 AM
$CRMD I don't get the relevance or importance of this. Some guy got a trophy that's worth $12 (2 shares basically)... The CEO is a god damn joke... This is a perfect example of Joe's narcissistic attitude. He's completely clueless and has 0 interest in the shareholders or the product.
1 · Reply
Noname2022
Noname2022 Mar. 14 at 6:50 PM
$CRMD $AKBA $FMS $DVA GovTrack currently shows about a 3% chance of enactment for the bill. Worth noting: Rep. Mike Kelly joined as a cosponsor on Jan 30 and sits on the House Ways & Means Health Subcommittee, the committee responsible for Medicare dialysis policy and the upcoming kidney hearing.
6 · Reply
Merlintrader
Merlintrader Mar. 14 at 5:01 PM
$CRMD https://www.merlintrader.com/run-up-biotech-masterclass/
0 · Reply
wolfofwestloop
wolfofwestloop Mar. 14 at 4:59 PM
$CRMD There were so many warning signs that this type of price collapse was coming. Elliott completely cashing out in June has to be the biggest one... Then Joe felt the need to just completely stomp on his own stock in early January... How did I think I was smarter than all these institutions??? It's looking like the people that said this has been approved in Europe for years were right.
1 · Reply
RIVNMomentumMan
RIVNMomentumMan Mar. 14 at 2:32 AM
$CRMD founded in 2006 by Antony Pfaffle. What kind of bs name is that, lol. This thing is nothing more than a slow bleeding dilution scam, lol.
0 · Reply
Latest News on CRMD
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript

Mar 5, 2026, 2:55 PM EST - 10 days ago

CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript


CorMedix Inc. (CRMD) Analyst/Investor Day Transcript

Feb 14, 2026, 2:37 AM EST - 4 weeks ago

CorMedix Inc. (CRMD) Analyst/Investor Day Transcript


CorMedix to Participate in Upcoming Investor Conferences

Feb 12, 2026, 8:30 AM EST - 4 weeks ago

CorMedix to Participate in Upcoming Investor Conferences


CorMedix Therapeutics Announces Share Repurchase Program

Feb 2, 2026, 8:30 AM EST - 5 weeks ago

CorMedix Therapeutics Announces Share Repurchase Program


CorMedix Therapeutics Announces Leadership and Board Updates

Jan 8, 2026, 8:05 AM EST - 2 months ago

CorMedix Therapeutics Announces Leadership and Board Updates


CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 11:11 AM EST - 4 months ago

CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript


CorMedix: Strong Adoption Curve And Policy Environment

Sep 22, 2025, 4:46 AM EDT - 6 months ago

CorMedix: Strong Adoption Curve And Policy Environment


CorMedix Announces Strategic Minority Investment in Talphera

Sep 8, 2025, 8:30 AM EDT - 6 months ago

CorMedix Announces Strategic Minority Investment in Talphera

TLPH


CorMedix: The Undervalued Breakthrough

Aug 26, 2025, 2:41 AM EDT - 7 months ago

CorMedix: The Undervalued Breakthrough


CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:16 PM EDT - 7 months ago

CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript


CorMedix to Buy Melinta Therapeutics for $300 Million

Aug 7, 2025, 10:49 AM EDT - 7 months ago

CorMedix to Buy Melinta Therapeutics for $300 Million


CorMedix Analyst Says Investors Could Be Further Rewarded

Jun 30, 2025, 2:24 PM EDT - 9 months ago

CorMedix Analyst Says Investors Could Be Further Rewarded


CorMedix Seems Significantly Undervalued

Jun 30, 2025, 2:14 PM EDT - 9 months ago

CorMedix Seems Significantly Undervalued


CorMedix Inc. Announces Proposed Public Offering of Common Stock

Jun 26, 2025, 4:01 PM EDT - 9 months ago

CorMedix Inc. Announces Proposed Public Offering of Common Stock


CorMedix inc. Announces Customer Implementation

Jun 23, 2025, 7:30 AM EDT - 9 months ago

CorMedix inc. Announces Customer Implementation


CorMedix: Exceeding Expectations

Jun 4, 2025, 12:41 PM EDT - 10 months ago

CorMedix: Exceeding Expectations


CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:59 AM EDT - 11 months ago

CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript


Brunoez
Brunoez Mar. 16 at 2:45 AM
$CRMD FWIW, I contacted my legislators in GA re: the Kidney Care Act. I received a reply from Raphael Warnock, and he indicated he will vote in favor.
0 · Reply
Noname2022
Noname2022 Mar. 16 at 12:17 AM
$CRMD Real world study, Rezzayo 91% effective (treatment) https://healix.net/wp-content/uploads/Hengel-et-al_IDWeek-2025_Rezafungin-Poster_09-24-2025.pdf
0 · Reply
Noname2022
Noname2022 Mar. 15 at 6:27 PM
$CRMD In HSCT prophylaxis studies, echinocandins show low Aspergillus breakthrough rates. In the randomized micafungin trial (van Burik 2004), 1 Aspergillus case occurred among 425 patients (~0.24%), vs 7 among 457 fluconazole patients (~1.5%). An MD Anderson caspofungin cohort (n=123) reported 3 Aspergillus infections (~2.4%). Micafungin and caspofungin are echinocandins, suggesting class activity. For comparison, posaconazole vs fluconazole showed 2.3% vs 7.0% aspergillosis (NEJM 2007). Rezafungin is also an echinocandin, with potential advantages including loading-dose exposure and higher tissue penetration.
0 · Reply
look_at_that_
look_at_that_ Mar. 15 at 4:34 PM
$CRMD Defencath will soon be the default lock solution for all eligible CVC patients at US Renal. I wonder if they are defining eligible as high risk FFS patients with a catheter or all FFS patients with a catheter across the board regardless of risk level. Either way it’s a positive.
0 · Reply
stevemail
stevemail Mar. 15 at 6:18 AM
$CRMD Joe needs to sell this for 1billion
0 · Reply
wolfofwestloop
wolfofwestloop Mar. 15 at 1:30 AM
$CRMD I don't get the relevance or importance of this. Some guy got a trophy that's worth $12 (2 shares basically)... The CEO is a god damn joke... This is a perfect example of Joe's narcissistic attitude. He's completely clueless and has 0 interest in the shareholders or the product.
1 · Reply
Noname2022
Noname2022 Mar. 14 at 6:50 PM
$CRMD $AKBA $FMS $DVA GovTrack currently shows about a 3% chance of enactment for the bill. Worth noting: Rep. Mike Kelly joined as a cosponsor on Jan 30 and sits on the House Ways & Means Health Subcommittee, the committee responsible for Medicare dialysis policy and the upcoming kidney hearing.
6 · Reply
Merlintrader
Merlintrader Mar. 14 at 5:01 PM
$CRMD https://www.merlintrader.com/run-up-biotech-masterclass/
0 · Reply
wolfofwestloop
wolfofwestloop Mar. 14 at 4:59 PM
$CRMD There were so many warning signs that this type of price collapse was coming. Elliott completely cashing out in June has to be the biggest one... Then Joe felt the need to just completely stomp on his own stock in early January... How did I think I was smarter than all these institutions??? It's looking like the people that said this has been approved in Europe for years were right.
1 · Reply
RIVNMomentumMan
RIVNMomentumMan Mar. 14 at 2:32 AM
$CRMD founded in 2006 by Antony Pfaffle. What kind of bs name is that, lol. This thing is nothing more than a slow bleeding dilution scam, lol.
0 · Reply
S2730
S2730 Mar. 13 at 11:17 PM
$CRMD KCAPA committee meeting next week. Not sure why this isn’t trending. That could completely erase the TDAPA cliff everyone has been freaking out about if it ends up going to a vote and gets passed. Add possible phase 3 data for Rezzayo to the mix, and we’re sitting on gold.
1 · Reply
Noname2022
Noname2022 Mar. 13 at 11:03 PM
$CRMD https://conference.nhia.org/exhibitor-spotlight-cormedix-therapeutics/
0 · Reply
Gencooliveoil
Gencooliveoil Mar. 13 at 8:25 PM
$CRMD retail is always the last to know. New Institutional Positions (Reported The following institutions initiated new positions in CRMD during the most recent reporting period: Lazard Asset Management LLC: 271,690 shares Del-Sette Capital Management: 210,831 shares Brandywine Global Investment Management LLC: 179,980 shares Phocas Financial Corp.: 171,087 shares & Walsh Asset Management: 137,894 shares Empowered Funds, LLC: 131,904 sharesD. E. Shaw & Co., Inc.: 106,374 shareSPacer Advisors Inc.: 253,896 shareVARCOV Co.: 170,890 shares Inspire Investing LLC: 107,259 shares State of Tennessee Department of Treasury: 19,205 sharSeveral existing institutional holders dramatically increased their stakes in recent months: Deep Track Capital, LP: Increased by +954.82% to a total of 5,274,076 shares.Goldman Sachs Group Inc.: Boosted holdings by +259.07% to 828,781 shares.Osaic Holdings, Inc.: Increased position by +458.17% to 262,601 shares Ops LLC: Increased holdings by +128.59% to 432,215 shares.
2 · Reply
Derek22us
Derek22us Mar. 13 at 8:09 PM
$CRMD An announcement of an increase in the share buyback numbers needed to jolt the short bassturds. Trench warfare today to gain a welcome few cents.
0 · Reply
168_swingit
168_swingit Mar. 13 at 6:34 PM
$CRMD Another loading zone!
0 · Reply
Noname2022
Noname2022 Mar. 13 at 6:26 PM
0 · Reply
GrindsToTheMax
GrindsToTheMax Mar. 13 at 5:54 PM
$CRMD specialty pharma developments tracked
0 · Reply
Stonehands
Stonehands Mar. 13 at 5:33 PM
$CRMD stuck in purgatory
0 · Reply
Noname2022
Noname2022 Mar. 13 at 5:10 PM
0 · Reply
CRMDepressed
CRMDepressed Mar. 13 at 4:25 PM
0 · Reply
Derek22us
Derek22us Mar. 13 at 4:08 PM
$CRMD Just look at the 700 share bass turd totally dominating the trading. This bloodsucking flea needs attention.
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Mar. 13 at 3:34 PM
$CRMD There are potential catalysts. This isn't some flailing, pre-revenue biotech suffering a news desert. Things will change, one way or another, following Rezzayo data. I'm down and discouraged, but not capitulating.
2 · Reply